Track topics on Twitter Track topics that are important to you
Following successful CRADA collaboration data in preclinical ALS models, GeNeuro exercises option with the National Institute of Neurological Disorders and Stroke (NINDS) to secure worldwide devel...
Robust cash position of €17.3 million as of June 30, 2018 All clinical and research activities funded through 3Q2019 Regulatory News: GeNeuro (Paris: GNRO) (Euronext Paris: CH0308403085 GNRO), a b.....
Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclero...
Q2 2018 operating revenues of €4.34 million (+195% vs. Q2 2017) €17.11 million cash at June 30, 2018 6-month results for Type 1 Diabetes clinical trial expected end September 2018 Regulatory News:...
Positive effects observed on key neuroprotection endpoints related to MS disease progression Neuroprotective effects also seen in non-active MS patients Confirmation of safety and tolerability Reg...
Are we closer to finding a cure for MS? Attend this webinar to find out. July 11, 2018 | 10:00am ET Discover insights from the experts at GeNeuro, a clinical stage pharmaceutical company developi...
SummaryGeNeuro SA GeNeuro is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflamm...
GeNeuro is a Swiss-based company created by Eclosion in 2006 as a spin-off of bioMÃ©rieux and co-funded by Eclosion and the Institut MÃ©rieux. GeNeuro is developing first-in-c...
We have published hundreds of GeNeuro SA news stories on BioPortfolio along with dozens of GeNeuro SA Clinical Trials and PubMed Articles about GeNeuro SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GeNeuro SA Companies in our database. You can also find out about relevant GeNeuro SA Drugs and Medications on this site too.